Loading stock data…
Karyopharm Therapeutics Inc. (KPTI)
$1.72-0.07 (-3.91%)
Market ClosedLast close Sep 8
Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Karyopharm Therapeutics Inc. in the Healthcare sector is trading at $1.72 with a market capitalization of $46M. Wall Street consensus targets $7.25 (4 analysts), implying a +321.5% move over the next 12 months. The stock is currently near its 52-week low of $1.70, remaining 75.8% below its 200-day moving average. On fundamentals, Piotroski 3/9 flags weak fundamentals, Altman Z in the distress zone. The Whystock Score of 25/100 signals elevated caution as multiple indicators diverge.
Ecosystem Influences
Sell-side targets imply +321.5% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $35.07M↑ | $34.08M↓ | $44.04M↑ | $37.93M↑ | $30.02M |
| Gross Profit | $33.72M↑ | $32.59M↓ | $41.93M↑ | $36.88M↑ | $28.71M |
| Operating Income | -$26.76M↓ | -$17.84M↓ | -$15.22M↑ | -$24.39M↑ | -$33.26M |
| Net Income | -$22.39M↑ | -$102.20M↓ | -$33.13M↑ | -$37.25M↓ | -$23.46M |
Peer Comparison
JNJUNHPFE
Fundamentals
Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develop...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$45.82M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
0.94
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-
Volume
Today's trading volume
1.01M
Recent News
Karyopharm Therapeutics (KPTI) Stock Fair Value Falls After Split Analyst Views On Trial Updates
Price targets on Karyopharm Therapeutics have swung sharply, with one bullish firm trimming its view from US$14 to US$11 and a more cautious house cutting from US$15 to US$3. These shifts reflect the split in analyst commentary, which now hinges on how investors weigh the myelofibrosis opportunity against the endometrial cancer setback and recent stock volatility. Read on to see how to follow this evolving narrative and what to watch as new data and regulatory decisions come through. Stay...
Karyopharm’s (KPTI) Big Cancer Bet Faces A Ticking Clock
On August 13, Karyopharm Therapeutics (NASDAQ:KPTI) held its second-quarter earnings call, and the story split cleanly in two. The company laid out a myelofibrosis combination therapy with data strong enough to earn an accelerated approval pathway from the FDA, alongside a cash position that funds operations only into September. A $15.8 million loan payment lands […]
Karyopharm (KPTI) Q2 2026 Earnings Call Transcript
Biotech pivots to hematology after endometrial cancer setback, faces debt deadline.
Karyopharm Therapeutics Inc. Q2 2026 Earnings Call Summary
Moby summary of Karyopharm Therapeutics Inc.'s Q2 2026 earnings call
Karyopharm Therapeutics Inc (KPTI) (Q2 2026) Earnings Call Highlights: SENTRY Trial Success and ...
Karyopharm reports promising myelofibrosis data and plans for accelerated approval sNDA, while navigating a tight cash position and failed endometrial cancer program.